Scott Saywell

Bio:

Scott Saywell has 30 years of experience in the biotech industry in various functional roles, including business and corporate development, marketing, and operations. Most recently, Scott was Executive Vice President of Corporate Development at Coherus Oncology. His prior roles include he was Chief Business Officer at Herophilus, Inc and Vice President of Corporate Development and Strategy at Theravance Biopharma, Inc. Across several companies, Scott has completed out-licensing and divestiture transactions with a combined potential value of more than $3B including nearly $1B in upfront payments. Prior to his business development roles, Scott led the commercialization planning and pre-launch activities for a first-in-class personalized cancer vaccine and contributed to establishing one of world’s first high-throughput DNA sequencing operations. Scott has a BS from UCLA and an MBA from the Kellogg School of Management, Northwestern University.